West Pharmaceutical Services (WST) Long-Term Deferred Tax (2009 - 2026)

West Pharmaceutical Services has disclosed Long-Term Deferred Tax across 18 years of filings, most recently posting $63.9 million for Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $63.9 million, up 145.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $63.9 million (up 145.77% YoY), and the FY2025 annual result was $38.4 million, up 47.69% from the prior year.
• Long-Term Deferred Tax came in at $63.9 million for Q1 2026 at West Pharmaceutical Services, up from $38.4 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $99.0 million in Q1 2023 to a low of $17.3 million in Q3 2023.
• The 5-year median for Long-Term Deferred Tax is $37.6 million (2024), against an average of $44.6 million.
• Across the five-year window, Long-Term Deferred Tax plunged 78.79% in 2024 and jumped 145.77% in 2026, its largest moves.
• West Pharmaceutical Services' Long-Term Deferred Tax stood at $65.6 million in 2022, then sank by 60.82% to $25.7 million in 2023, then advanced by 1.17% to $26.0 million in 2024, then jumped by 47.69% to $38.4 million in 2025, then jumped by 66.41% to $63.9 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $63.9 million (Q1 2026), $38.4 million (Q4 2025), and $27.9 million (Q3 2025), per Business Quant data.